Nitrated Indenoisoquinolines as Topoisomerase I Inhibitors: A Systematic Study and Optimization
作者:Andrew Morrell、Michael Placzek、Seth Parmley、Smitha Antony、Thomas S. Dexheimer、Yves Pommier、Mark Cushman
DOI:10.1021/jm070361q
日期:2007.9.1
The biological activity of indenoisoquinoline topoisomerase I (Topl) inhibitors can be greatly enhanced depending on the choice of substituents on the aromatic rings and lactam side chain. Previously, it was discovered that a 3-nitro group and a 9-methoxy group afforded enhanced biological activity. In the present investigation, indenoisoquinoline analogues were systematically prepared using combinations of nitro groups, methoxy groups, and hydrogen atoms in an effort to understand the contribution of each group toward cytotoxicity and Top I inhibition. Analysis of the biological results suggests that the nitro group is important for Top I inhibition and the methoxy group improves cytotoxicity. In addition, previously identified structure-activity relationships were utilized to select favorable lactam side chain functionalities for incorporation on the aromatic skeleton of analogues in this study. As a result, this investigation has provided optimal Topl inhibitors equipotent to camptothecin that demonstrate low nanomolar cytotoxicities toward cancer cells.
PATIENT SELECTION FOR TREATMENT OF MYC POSITIVE CANCERS WITH INDENOISOQUINOLINES
申请人:Purdue Research Foundation
公开号:US20210382058A1
公开(公告)日:2021-12-09
The present disclosure is directed to a method for selecting a patient with cancer for treatment with a compound of formula (I) by determining if the patient's cancer cells are MYC-positive and when the MYC promoter sequence in those cancer cells contains a nucleic acid sequence capable of forming a MYC G-quadruplex (MYC G4) (i.e. are MYC G4-positive) and treating the patient with a compound of formula (I).